Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has emerged as an effective therapy for improving glycemic control and reducing body weight, yet its effects on cardiovascular outcomes remain uncertain. To address this gap, a study evaluated cardiovascular outcomes associated with tirzepatide treatment in a large population of 13,299 patients with a mean age of 64 years. The study showed that tirzepatide resulted in a lower incidence of primary cardiovascular end-point events compared with dulaglutide (12.2% vs 13.1%; hazard ratio, 0.92), meeting criteria for noninferiority but not superiority.
Overall adverse event rates were similar between groups, although gastrointestinal adverse events were more frequent with tirzepatide. These findings suggest that in patients with type 2 diabetes and established…
